Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the her2-positive breast cancer market size evolved in recent years?

Over the past few years, the market size of HER2-positive breast cancer has seen a substantial increase. The market is projected to escalate from $10.21 billion in 2024 to $10.96 billion in 2025 at a CAGR of 7.34%. The factors contributing to the growth in the historical period include the rise in early detection and diagnosis, increased awareness about HER2-positive subtypes, expansion in research and development investment, a heightening acceptance of precision medicine, and a growing emphasis on bettering patient outcomes.

What are the predictions for the her2-positive breast cancer market size in the coming years?

Anticipations are high for a significant escalation in the HER2-positive breast cancer market, which is predicted to be valued at $14.41 billion by 2029, progressing at a compound annual growth rate (CAGR) of 7.08%. Factors propelling growth in the anticipated period encompass the expanding demand for non-invasive monitoring through liquid biopsy, the rise in acceptance of combination treatments, an expanded emphasis on immunotherapies and unique drug formations, the growing utility of liquid biopsy methods for non-invasive monitoring, and a rise in the quantity of dedicated cancer treatment centers. Key trends in the prediction period include advancements in targeted therapies, new formulations, breakthroughs in immunotherapy strategies, the creation of innovative HER2-focused therapies, and progress in biomarkers for enhanced patient stratification.

Get your her2-positive breast cancer market report here!

https://www.thebusinessresearchcompany.com/report/her2-positive-breast-cancer-global-market-report

What key factors are fueling the growth of the her2-positive breast cancer market?

The anticipated widespread acceptance of immunotherapy is predicted to fuel the HER2-positive breast cancer market’s expansion. Immunotherapy is a therapeutic intervention that boosts or modifies the immune system’s natural capacity to combat diseases like cancer, infections, and autoimmune disorders. This treatment method’s popularity stems from its ability to strengthen the immune system’s propensity to detect and destroy cancer cells, offering superior efficacy and fewer side-effects than traditional therapies. In the context of HER2-positive breast cancer, immunotherapy enhances the body’s immune system’s capacity to identify and combat cancer cells that overexpress HER2, thus ameliorating treatment results and lowering the chances of cancer rebound. For instance, the American Association for Cancer Research, a US-based body, reported in July 2023 that the FDA has cleared 11 immune checkpoint inhibitors (ICIs) for use, with at least one ICI ratified for treating 20 distinct cancer types and any solid tumor carrying specific molecular traits. Consequently, the widespread acceptance of immunotherapy is bolstering the HER2-positive breast cancer market’s growth.

How is the global her2-positive breast cancer market divided into key segments?

The HER2-positive breast cancer market covered in this report is segmented –

1) By Treatment Type: Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types

2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End User

Subsegments:

1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors

2) By Chemotherapy: Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens

3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy

4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation, Cancer Vaccines

5) By Other Treatment Types: Radiation Therapy, Stem Cell Therapy, Hyperthermia Treatment, Gene Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery)

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20832&type=smp

Who are the key firms paving the way for growth in the her2-positive breast cancer market?

Major companies operating in the HER2-positive breast cancer market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Co. Ltd., Incyte Corporation, BioNTech SE, MacroGenics Inc., CStone Pharmaceuticals Co. Ltd., Sorrento Therapeutics Inc., Syndax Pharmaceuticals Inc., Fate Therapeutics Inc., Ambrx Biopharma Inc.

What emerging trends are influencing the growth of the her2-positive breast cancer market?

Major companies operating in the HER2-positive breast cancer market are focused on developing innovative therapies, such as her2-directed antibody-drug conjugates (ADCs), to streamline and enhance the treatment process for patients. HER2-directed antibody-drug conjugates (ADCs) are targeted cancer therapies that link an antibody specific to HER2 with a cytotoxic drug, delivering the drug directly to HER2-positive cancer cells for more effective treatment. For instance, in January 2024, AstraZeneca India Pharma Ltd., an India-based biopharmaceutical company, launched Trastuzumab deruxtecan. This innovative therapy was developed through a collaboration between AstraZeneca and Daiichi Sankyo. Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate (ADC), which delivers a cytotoxic drug directly to HER2-positive cancer cells, offering a more targeted and effective treatment for patients.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20832

What regions are contributing significantly to the growth of the her2-positive breast cancer market?

North America was the largest region in the HER2- positive breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-positive breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Breast Cancer Drugs Global Market Report 2025

https://thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Breast Cancer Diagnostics Global Market Report 2025

https://thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Breast Imaging Devices Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/breast-imaging-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: